KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Bionano Genomics (BNGO) Operating Expenses (2017 - 2025)

Bionano Genomics (BNGO) has disclosed Operating Expenses for 9 consecutive years, with $11.9 million as the latest value for Q4 2025.

  • Quarterly Operating Expenses fell 22.29% to $11.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $46.5 million through Dec 2025, down 55.42% year-over-year, with the annual reading at $46.5 million for FY2025, 55.42% down from the prior year.
  • Operating Expenses hit $11.9 million in Q4 2025 for Bionano Genomics, roughly flat from $11.9 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $116.0 million in Q3 2023 to a low of $11.3 million in Q2 2025.
  • Historically, Operating Expenses has averaged $29.7 million across 5 years, with a median of $28.2 million in 2021.
  • Biggest five-year swings in Operating Expenses: skyrocketed 241.48% in 2023 and later tumbled 69.43% in 2024.
  • Year by year, Operating Expenses stood at $29.0 million in 2021, then surged by 35.52% to $39.3 million in 2022, then crashed by 30.36% to $27.4 million in 2023, then tumbled by 43.93% to $15.4 million in 2024, then fell by 22.29% to $11.9 million in 2025.
  • Business Quant data shows Operating Expenses for BNGO at $11.9 million in Q4 2025, $11.9 million in Q3 2025, and $11.3 million in Q2 2025.